Showing results (971-980 of 1,008) with videos related to
Sort By:
Pageof 101
Frontiers in Immunology|July 26, 2022
Restricted T-Cell Repertoire in the Epicardial Adipose Tissue of Non-ST Segment Elevation Myocardial Infarction PatientsDaniela Pedicino, Anna Severino, Gabriele Di Sante, et al.Cell|October 13, 2009
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesisCagla Eroglu, Nicola J Allen, Michael W Susman, et al.Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.Plos One|July 11, 2014
Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphomaJustin Rendleman, Yevgeniy Antipin, Boris Reva, et al.Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.British Journal of Haematology|October 28, 2024
Haematopoietic cell transplantation for 106 infants and preschoolers with acquired and inherited bone marrow failuresGisele Loth, Cilmara C K Dumke, Rafaella R Muratori, et al.JCO Precision Oncology|July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell CarcinomaRitesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.Cancer Research|June 24, 2010
Genomic and biological characterization of exon 4 KRAS mutations in human cancerManickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerMark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancerLecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.Pageof 101